Regencell Bioscience Holdings Limited (RGC) Income Statement
RGC FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsRGC revenue and net income
RGC profit margins
RGC growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RGC quarterly EPS vs estimates
Regencell Bioscience beat the analyst EPS estimate in 2 of the last 2 quarters. Next report: October 30, 2026.
RGC income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.16B | $3.20B |
| Cost of revenue | $404,543 | $392,743 | $745,588 | $769,687 | $604,397 | $26,456 | $9,516 | — | $123.0M | $1.23B |
| Gross profit | −$404,543 | −$392,743 | −$745,588 | −$769,687 | −$604,397 | −$26,456 | −$9,516 | — | $3.04B | $1.97B |
| Research & development | $1.3M | $948,289 | $1.1M | $1.6M | $2.5M | $438,323 | $386,230 | $228,223 | — | — |
| Sales, general & admin | — | $2.4M | $2.9M | $4.7M | $5.1M | $943,039 | $426,141 | $162,767 | $86.6M | $512.2M |
| Total operating expenses | $11.3M | $3.4M | $4.0M | $6.3M | $7.6M | $1.4M | $812,371 | $390,990 | $1.31B | $1.63B |
| Operating income | −$11.7M | −$3.8M | −$4.7M | −$6.3M | −$7.6M | −$1.4M | −$812,371 | −$390,990 | $271.7M | $344.2M |
| Interest expense | — | — | — | — | $23,215 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$11.7M | −$3.6M | −$4.4M | −$6.1M | −$7.6M | −$1.3M | −$812,371 | −$390,990 | $213.9M | $281.7M |
| Income taxes | — | — | $312,126 | −$191,199 | −$171,827 | −$210,102 | −$1 | −$391 | $101.6M | $111.2M |
| Net income | −$11.7M | −$3.6M | −$4.3M | −$5.9M | −$7.4M | −$1.3M | −$812,371 | −$390,990 | $112.3M | $170.4M |
| EBITDA | −$11.3M | −$3.2M | −$3.6M | −$5.3M | −$7.0M | −$1.4M | −$802,855 | −$390,990 | $468.7M | $512.3M |
| EPS (diluted) | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.02 | $0.00 | −$0.08 | −$0.01 | — | $0.03 |
| Gross margin | — | — | — | — | — | — | — | — | 96.1% | 61.6% |
| Operating margin | — | — | — | — | — | — | — | — | 8.6% | 10.8% |
| Net margin | — | — | — | — | — | — | — | — | 3.6% | 5.3% |
| Sep '26 | Mar '26 | Sep '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $363,704 | $40,839 | — | — | — | — | — | — | $769,687 | $769,687 | — | — |
| Gross profit | −$363,704 | −$40,839 | — | — | — | — | — | — | −$769,687 | −$769,687 | — | — |
| Research & development | $883,597 | $416,030 | $440,908 | $507,381 | $253,691 | $291 | $291 | $242 | $242 | $231,571 | $116 | $1.4M |
| Sales, general & admin | — | — | $1.4M | $1.5M | $735,228 | $963 | $758 | $914 | $914 | $1.8M | $1,124 | $2.1M |
| Total operating expenses | $6.0M | $5.3M | $1.8M | $2.0M | $988,918 | $1,212 | $1,212 | $1,156 | $1,156 | $2.1M | $1,374 | $3.4M |
| Operating income | −$6.4M | −$5.3M | −$1.8M | −$2.0M | −$988,918 | −$1,212 | −$1,212 | −$1,156 | −$1,156 | −$2.8M | −$1,422 | −$3.4M |
| Income before taxes | −$6.4M | −$5.3M | −$1.7M | −$1.9M | −$926,807 | −$1,088 | −$1,088 | −$1,093 | −$1,093 | −$2.7M | −$1,374 | −$3.3M |
| Income taxes | — | — | — | — | $57,887 | — | — | −$60 | −$60 | −$52 | −$52 | −$44 |
| Net income | −$6.4M | −$5.3M | −$1.7M | −$1.9M | −$926,807 | −$1,117 | −$1,117 | −$1,033 | −$1,033 | −$2.6M | −$1,322 | −$3.2M |
| EBITDA | −$6.0M | −$5.3M | −$1.7M | −$1.8M | −$912,473 | $158,000 | −$1,139 | −$1.2M | −$1.1M | −$3.4M | −$1.4M | −$5.0M |
| EPS (diluted) | — | — | $0.00 | — | $0.00 | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RGC's financial statements (latest annual report filed October 7, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RGC financial results
Regencell Bioscience reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $11.7 million. Diluted earnings per share came to −$0.02.
See the RGC stock overview for the latest quote and news, or the RGC chart for price history and technical indicators.
RGC income statement FAQ
Does Regencell Bioscience have revenue?
Regencell Bioscience reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is Regencell Bioscience profitable?
No. Regencell Bioscience reported a net loss of $11.7 million in fiscal 2026.
How much does Regencell Bioscience spend on research and development?
Regencell Bioscience spent $1.3 million on research and development in fiscal 2026.
What are Regencell Bioscience's earnings per share?
Regencell Bioscience earned $-0.02 per diluted share in fiscal 2026, compared with $-0.01 a year earlier.
When will Regencell Bioscience report its next earnings?
Regencell Bioscience is expected to report results for the quarter ending September 30, 2026 on October 30, 2026.
When does Regencell Bioscience's fiscal year end?
Regencell Bioscience's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on October 7, 2026.